Literature DB >> 27713887

New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Francisco Valenzuela-Sánchez1, Blanca Valenzuela-Méndez2, Juan Francisco Rodríguez-Gutiérrez3, Ángel Estella-García1, María Ángela González-García4.   

Abstract

Mid-regional pro-adrenomedullin (MR-proADM) has a good biomarker profile: its half-life is several hours, and its plasma concentrations can be determined in clinical practice, it is essentially irrelevant, but proportionally represents the levels and activity of adrenomedullin (ADM). ADM synthesis is widely distributed in tissues, including bone, adrenal cortex, kidney, lung, blood vessels and heart. Its fundamental biological effects include vasodilator, positive inotropic, diuretic, natriuretic and bronchodilator. It has been described high levels in septic patients, interacting directly with the relaxation of vascular tone, triggering hypotension of these patients. It is also found high levels in other diseases such as hypertension, heart failure, respiratory failure, renal failure, cirrhosis and cancer. MR-proADM has been identified as a prognostic marker, stratifying the mortality risk in patients with sepsis in emergency department (ED) and ICU. Evolutionary MR-proADM levels and clearance marker to the 2nd-5th days of admission help to determine the poor performance and the risk of mortality in patients with severe sepsis admitted to the ICU. The MR-proADM levels are more effective than procalcitonin (PCT) and C-reactive protein (CRP) levels to determine an unfavorable outcome and the risk of mortality in patients with sepsis admitted to the ICU. It has also proved useful in patients diagnosed with organ dysfunction of infectious etiology. MR-proADM levels are independent of the germ conversely it is related to the magnitude of organ failure and therefore severity. We consider advisable incorporating the MR-proADM the panel of biomarkers necessary for the diagnosis and treatment of critically ill patients admitted to the ICU with severe sepsis. The combined PCT and MR-proADM levels could represent a valid tool in the clinical practice to timely identify patients with bacterial infections and guide the diagnosis and treatment of sepsis and septic shock.

Entities:  

Keywords:  Mid-regional pro-adrenomedullin (MR-proADM); adrenomedullin (ADM); biomarker; sepsis; septic shock

Year:  2016        PMID: 27713887      PMCID: PMC5050192          DOI: 10.21037/atm.2016.08.65

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  61 in total

Review 1.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

2.  Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage.

Authors:  Bernhard Brell; Bettina Temmesfeld-Wollbrück; Iris Altzschner; Eckehard Frisch; Bernd Schmeck; Andreas C Hocke; Norbert Suttorp; Stefan Hippenstiel
Journal:  Crit Care Med       Date:  2005-04       Impact factor: 7.598

3.  Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients.

Authors:  Caroline Guignant; Nicolas Voirin; Fabienne Venet; Françoise Poitevin; Christophe Malcus; Julien Bohé; Alain Lepape; Guillaume Monneret
Journal:  Intensive Care Med       Date:  2009-08-07       Impact factor: 17.440

4.  Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.

Authors:  Borja Suberviola; Alvaro Castellanos-Ortega; Javier Llorca; Fernando Ortiz; David Iglesias; Belen Prieto
Journal:  Swiss Med Wkly       Date:  2012-03-19       Impact factor: 2.193

5.  Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure.

Authors:  F Pousset; F Masson; O Chavirovskaia; R Isnard; A Carayon; J L Golmard; P Lechat; D Thomas; M Komajda
Journal:  Eur Heart J       Date:  2000-06       Impact factor: 29.983

6.  Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners.

Authors:  R Pio; A Martinez; E J Unsworth; J A Kowalak; J A Bengoechea; P F Zipfel; T H Elsasser; F Cuttitta
Journal:  J Biol Chem       Date:  2000-12-14       Impact factor: 5.157

7.  Mechanisms of adrenomedullin antimicrobial action.

Authors:  Robert P Allaker; Paul W Grosvenor; David C McAnerney; Barry E Sheehan; Bakula H Srikanta; Keith Pell; Supriya Kapas
Journal:  Peptides       Date:  2005-10-13       Impact factor: 3.750

8.  Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD.

Authors:  Daiana Stolz; Mirjam Christ-Crain; Nils G Morgenthaler; David Miedinger; Jörg Leuppi; Christian Müller; Roland Bingisser; Joachim Struck; Beat Müller; Michael Tamm
Journal:  Chest       Date:  2008-05-19       Impact factor: 9.410

9.  Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.

Authors:  Philipp Schuetz; Marcel Wolbers; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Thomas Fricker; Claudine Blum; Ursula Schild; Nils G Morgenthaler; Ronald Schoenenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Mueller
Journal:  Crit Care       Date:  2010-06-08       Impact factor: 9.097

10.  Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination.

Authors:  Silvia Angeletti; Giordano Dicuonzo; Marta Fioravanti; Marina De Cesaris; Marta Fogolari; Alessandra Lo Presti; Massimo Ciccozzi; Lucia De Florio
Journal:  Dis Markers       Date:  2015-11-09       Impact factor: 3.434

View more
  20 in total

1.  Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease).

Authors:  Zhihui Xie; Wei-Sheng Chen; Yuzhi Yin; Eunice C Chan; Kaoru Terai; Lauren M Long; Timothy G Myers; Arkadiusz Z Dudek; Kirk M Druey
Journal:  J Leukoc Biol       Date:  2018-01-23       Impact factor: 4.962

Review 2.  Current and future circulating biomarkers for cardiac amyloidosis.

Authors:  Marco Luciani; Luca Troncone; Federica Del Monte
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

3.  Biomarkers in Shock Patients and Their Value as A Prognostic Tool; A Prospective Multi-Center Cohort Study.

Authors:  Ana Maria Navio Serano; Joaquín Valle Alonso; Gustavo Rene Piñero; Alejandro Rodriguez Camacho; Josefa Soriano Benet; Manuel Vaquero
Journal:  Bull Emerg Trauma       Date:  2019-07

4.  Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness.

Authors:  Giuseppe Lippi; Brandon Michael Henry
Journal:  Intern Emerg Med       Date:  2021-05-07       Impact factor: 3.397

5.  Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation.

Authors:  Sebastian O Decker; Annette Sigl; Christian Grumaz; Philip Stevens; Yevhen Vainshtein; Stefan Zimmermann; Markus A Weigand; Stefan Hofer; Kai Sohn; Thorsten Brenner
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

6.  Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study.

Authors:  Sara Graziadio; Rachel Amie O'Leary; Deborah D Stocken; Michael Power; A Joy Allen; A John Simpson; David Ashley Price
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

Review 7.  Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review.

Authors:  Uğur Önal; Francisco Valenzuela-Sánchez; Kalwaje Eshwara Vandana; Jordi Rello
Journal:  Healthcare (Basel)       Date:  2018-09-03

8.  Mid-Regional Proadrenomedullin and Mid-Regional Proatrial Natriuretic Peptide Clearance Predicts Poor Outcomes Better Than Single Baseline Measurements in Critically Ill Patients With Pneumonia: A Retrospective Cohort Study.

Authors:  Jos Van Oers; Johannes Krabbe; Evelien Kemna; Yvette Kluiters; Piet Vos; Dylan De Lange; Armand Girbes; Albertus Beishuizen
Journal:  Cureus       Date:  2021-05-28

9.  Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.

Authors:  Jacopo Maria Legramante; Maria Mastropasqua; Beniamino Susi; Ottavia Porzio; Marta Mazza; Grazia Miranda Agrippino; Cartesio D Agostini; Antonella Brandi; Germano Giovagnoli; Vito Nicola Di Lecce; Sergio Bernardini; Marilena Minieri
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

10.  Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.

Authors:  Bruno Viaggi; Daniele Poole; Omar Tujjar; Silvia Marchiani; Agostino Ognibene; Stefano Finazzi
Journal:  PLoS One       Date:  2018-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.